EMA Authorised: Prolia (denosumab) — Amgen Europe B.V.

View source ↗

Summary

EMA authorises Prolia (denosumab) for osteoporosis-related indications, confirming market approval in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Osteoporosis Postmenopausal

Drugs mentioned

• Prolia (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis. MAH: Amgen Europe B.V.. Decision date: 15/01/2026